At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 100 target
Drug / intervention
ZG006 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Study Evaluating the Safety and Efficacy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
In Brief
A Phase 1 clinical trial evaluating ZG006 and Serplulimab for Small Cell Lung Cancer. Currently recruiting, targeting 100 participants across 1 site.
Detailed Summary
This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
2026202720282029
First PostedNov 2025
Enrollment StartApr 2026
TodayJul 2026
Primary CompletionDec 2028
First PostedNov 17, 2025
Enrollment StartApr 21, 2026
Primary CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2.6 yearsPosted 7 months agoPrimary completion in 2.4 years
Interventions
ZG006drug
ZG006 will be administered as an IV infusion.
Serplulimabdrug
Serplulimab will be administered as an IV infusion.